UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase

Blood, 2011-04, Vol.117 (17), p.4658-4666

2011

Volltextzugriff (PDF)

552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A334-A335

2020

Volltextzugriff (PDF)

A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR

Cancer research (Chicago, Ill.), 2009-05, Vol.69 (9), p.3856-3865

2009

Volltextzugriff (PDF)

Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL―Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors

Cancer research (Chicago, Ill.), 2009-08, Vol.69 (16), p.6546-6555

2009

Volltextzugriff (PDF)

Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo

Cancer research (Chicago, Ill.), 2006-06, Vol.66 (12), p.6304-6311

2006

Volltextzugriff (PDF)

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Blood, 2022-05, Vol.139 (18), p.2770-2781

2022

Volltextzugriff (PDF)

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

Journal of medicinal chemistry, 2021-03, Vol.64 (5), p.2501-2520

2021

Volltextzugriff (PDF)

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Science translational medicine, 2021-09, Vol.13 (611), p.eaba7791

2021

Volltextzugriff (PDF)

Abstract 1523: Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through Type I IFN pathway activation

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1523-1523

2019

Volltextzugriff (PDF)

Abstract 3252: TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3252-3252

2019

Volltextzugriff (PDF)

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Blood, 2021-11, Vol.138 (Supplement 1), p.2268-2268

2021

Volltextzugriff (PDF)

Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA)

Vaccine, 2004-03, Vol.22 (9), p.1199-1205

2004

Volltextzugriff (PDF)

Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5

The Journal of biological chemistry, 2004-12, Vol.279 (53), p.55594-55601

2004

Volltextzugriff (PDF)

Quest for molecular markers in adult soft tissue tumors

Cancer biology & therapy, 2006-02, Vol.5 (2), p.234-235

2006

Volltextzugriff (PDF)

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2742-2742

2021

Volltextzugriff (PDF)

Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-319-LB-319

2019

Volltextzugriff (PDF)

Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3079-3079

2019

Volltextzugriff (PDF)

Apoptotic pathways in tumor progression and therapy

Advances in experimental medicine and biology, 2008, Vol.615, p.47

2008

Volltextzugriff (PDF)

Abstract 1147: Probing the roles of SUMOylation in cancer cell biology using a selective SUMO activating enzyme inhibitor

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1147-1147

2017

Volltextzugriff (PDF)

Abstract B154: Application of preclinical combination pharmacokinetic(PK)/efficacy(E) modeling to investigate and translate the preclinical scheduling effect for MLN1117 and Taxotere combination

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.B154-B154

2015

Volltextzugriff (PDF)

Abstract A169: Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A169-A169

2013

Volltextzugriff (PDF)

Analysis of TNF-related apoptosis-inducing ligand in vivo through bone marrow transduction and transplantation

Methods in enzymology, 2008, Vol.446, p.315

2008

Volltextzugriff (PDF)

Abstract 2909: ApoFLIP: A bioactive peptide that restarts the apoptotic machinery in cancer cells

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2909-2909

2010

Volltextzugriff (PDF)

Abstract 4514: Proteasome inhibition causes regression of leukemia in part through regulation of forkhead tumor suppressors

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4514-4514

2010

Volltextzugriff (PDF)

Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis

Biochemical journal, 1996-09, Vol.318 ( Pt 3) (3), p.797-803

1996

Volltextzugriff (PDF)

1 – 25 von 170

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(152)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(107)
Physical Sciences
(45)
Life Sciences & Biomedicine
(44)
Chemistry
(34)
Technology
(30)
Humans
(18)
Animals
(17)
Physics
(17)
Materials Science
(16)
Materials Science, Multidisciplinary
(16)
Engineering
(14)
Chemistry, Physical
(12)
Science & Technology - Other Topics
(12)
Chemistry, Multidisciplinary
(11)
Mice
(11)
Immunology
(10)
Exact Sciences And Technology
(9)
Nanoscience & Nanotechnology
(8)
Biochemistry & Molecular Biology
(7)
Cell Line
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(10)
Chemical Communications
(7)
Cheminform
(5)
Blood
(4)
Energy & Fuels
(4)
Angewandte Chemie
(3)
Organic Letters
(3)
Physical Chemistry Chemical Physics : Pccp
(3)
Acs Applied Materials & Interfaces
(2)
Analyst
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase

552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

A Double Hit to Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR

Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL―Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors

Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Abstract 1523: Inhibition of SUMOylation by TAK-981 induces antitumor innate immune responses by modulating macrophage and NK cell function through Type I IFN pathway activation

Abstract 3252: TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming

The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models

Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA)

Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5

Quest for molecular markers in adult soft tissue tumors

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor

Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model

Apoptotic pathways in tumor progression and therapy

Abstract 1147: Probing the roles of SUMOylation in cancer cell biology using a selective SUMO activating enzyme inhibitor

Abstract B154: Application of preclinical combination pharmacokinetic(PK)/efficacy(E) modeling to investigate and translate the preclinical scheduling effect for MLN1117 and Taxotere combination

Abstract A169: Assessment of genotype-correlated sensitivity to the investigational PI3Kα selective inhibitor MLN1117 in preclinical models

Analysis of TNF-related apoptosis-inducing ligand in vivo through bone marrow transduction and transplantation

Abstract 2909: ApoFLIP: A bioactive peptide that restarts the apoptotic machinery in cancer cells

Abstract 4514: Proteasome inhibition causes regression of leukemia in part through regulation of forkhead tumor suppressors

Translocation of cytosolic phospholipase A2 to the nuclear envelope elicits topographically localized phospholipid hydrolysis

Suchergebnisse filtern